Sinopharm Group (1099) Q1 2026 earnings summary

Executive summary

• Revenue for the three months ended 31 March 2026 was RMB 16.99 billion, up 1.23% year-over-year.

• Operating profit declined 20.41% year-over-year to RMB 220.19 million.

• Total comprehensive income attributable to owners fell 7.47% year-over-year to RMB 115.15 million.

Financial highlights

• Net cash flow from operating activities was negative RMB 4.57 billion, compared to negative RMB 3.13 billion in the prior year period.

• Total assets at period end were RMB 59.49 billion, up 3.82% from the beginning of the period.

• Total equity attributable to owners was RMB 8.42 billion, a 1.39% increase from the start of the period.

Key financial ratios and metrics

• Revenue growth was 1.23% year-over-year for the quarter.

• Operating profit margin declined due to a 20.41% drop in operating profit.

• Net cash outflow from operations increased by 45.86% year-over-year.